We aimed to identify WMH locations associated with vascular risk or cerebral amyloid-β1-42 (Aβ42)-positive status.

Using a similar approach to that adopted in STRIVE-1, we updated the guidance on neuroimaging of vascular changes in studies of ageing and neurodegeneration to create STRIVE-2.

We examined whether key vascular and genetic risk impact the association between cerebral amyloid burden and plasma aβ (amyloid β) 42/40 in nondemented older adults.

We examined the diagnostic accuracy of plasma placental growth factor (PlGF) within the MarkVCID Consortium.

We aimed to establish whether the effects of high blood pressure in the brain are evident as early as the fifth decade of life.

A new method was developed to define volumes of interest from high-resolution three-dimensional T1-weighted MR images.